Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
October 31, 2014 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 31, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
October 14, 2014 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
October 09, 2014 08:22 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
October 06, 2014 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
September 18, 2014 08:26 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
August 13, 2014 10:18 ET
|
Capricor Therapeutics, Inc.
Reports Encouraging Results From Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License With Cedars-Sinai Medical Center for Exosomes IP Portfolio
Conference Call Scheduled for...
Capricor Therapeutics to Hold Second Quarter 2014 Business Update Conference Call on August 13, 2014 at 4:30 p.m. Eastern Time
August 04, 2014 08:27 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today...
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
July 16, 2014 07:59 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 16, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
June 23, 2014 09:02 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 23, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
June 19, 2014 13:28 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 19, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...